SLC5A2 and obesity disorder: Furthermore, adults with obesity and without diabetes had similar plasma glucagon when treated with SGLT2 inhibitors or placebo.71 The intermediate group with impaired fasting glucose had a small but significant decrease in fasting plasma glucose with no change in fasting plasma insulin or glucagon.6 Lastly, adults with type 2 diabetes had a significant decrease in fasting plasma glucose and a significant increase in fasting plasma glucagon within 1 day of the introduction of SGLT2 inhibition.6